The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 02, 2006
Filed:
Jul. 12, 2000
Daniel E. H. Afar, Pacific Palisades, CA (US);
Rene S. Hubert, Los Angeles, CA (US);
Kahan Leong, Playa Del Rey, CA (US);
Arthur B. Raitano, Los Angeles, CA (US);
Douglas Saffran, Los Angeles, CA (US);
Stephen C. Mitchell, Santa Monica, CA (US);
Aya Jakobovits, Beverly Hills, CA (US);
Mary Faris, Los Angeles, CA (US);
Igor Vivanco, Los Angeles, CA (US);
Daniel E. H. Afar, Pacific Palisades, CA (US);
Rene S. Hubert, Los Angeles, CA (US);
Kahan Leong, Playa Del Rey, CA (US);
Arthur B. Raitano, Los Angeles, CA (US);
Douglas Saffran, Los Angeles, CA (US);
Stephen C. Mitchell, Santa Monica, CA (US);
Aya Jakobovits, Beverly Hills, CA (US);
Mary Faris, Los Angeles, CA (US);
Igor Vivanco, Los Angeles, CA (US);
Agensys, Inc., San Diego, CA (US);
Abstract
Compositions for the diagnosis and therapy of prostate and colon cancer, derived from or based on a novel prostate-specific, androgen-related, cell membrane associated and secreted serine protease termed 20P1F12/TMPRSS2 are described. A full length cDNA comprising the entire coding sequence of the 20P1F12/TMPRSS2 gene (also designated 20P1F12-GTC1 herein) is provided (FIG.). Among the compositions provided are antibodies that bind to 20P1F12/TMPRSS2 proteins and polypeptide fragments thereof, including antibodies labeled with a detectable marker or toxin or therapeutic composition. The invention also provides prognostic and diagnostic methods of examining a biological sample for evidence of disregulated cellular growth by comparing the status of 20P1F12/TMPRSS2 in the biological sample to the status of 20P1F12/TMPRSS2 in a corresponding normal sample, wherein alterations in the status of 20P1F12/TMPRSS2 in the biological sample are associated with disregulated cellular growth. The invention further provides various therapeutic compositions and strategies for treating prostate cancer, including particularly, 20P1F12/TMPRSS2 polypeptide and anti-20P1F12/TMPRSS2 antibody therapy methods and compositions, cancer vaccines, and small molecule therapy.